Purchase this article with an account.
J. G. McHenry, R. Weinstein; Infliximab, Optic Neuropathy and Giant Cell Arteritis. Invest. Ophthalmol. Vis. Sci. 2007;48(13):921.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To show a case of optic neuropathy intolerant of steroids successfully treated with infliximab.
The records of a 68 year old patient with temporal pain, jaw claudication and visual loss treated with infliximab were reviewed.
Visual fields normalized and symptoms immediately improved.
Infliximab is an indirect T cell inhibitor. It is a mouse-human IgG1 chimeric anti-tumor necrosis (TNFa) factor monoclonal antibody. It inhibits the binding of TNFa with its receptor. TNFa induces interleukin 1 and 6 which in turn lead to T cell migration. As giant cell arteritis is a T cell mediated disease, infliximab may offer a way to arrest visual loss in emergent giant cell arteritis, as its response may occur within hours.
This PDF is available to Subscribers Only